Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

GRI Bio

GRI Bio?uq=WouuG6Ev
2009 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE (Cancelled)
Description

Developer of therapies created to treat inflammatory diseases. The company's cell-based therapies are developed to treat liver disease and autoimmunity deficiencies by targeting the regulation of NKT cells.

Website
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 2223 Avenida De La Playa
  • Suite 105
  • La Jolla, CA 92037
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore GRI Bio’s full profile, request a free trial.

GRI Bio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) Cancelled Generating Revenue
1. Angel (individual) 17-Apr-2015 00.000 00.000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

GRI Bio Executive Team (4)

Name Title Board
Seat
Contact
Info
Sean Edwards JD President & Co-Chief Executive Officer
Vipin Chaturvedi Ph.D Chief Scientific Officer, Board Member and Co-Founder
Marc Hertz Ph.D Co-Founder, Chairman & Chief Executive Officer
Albert Agro Ph.D Senior Vice President of Clinical Development, Board Member and Co-Founder

GRI Bio Board Members (5)

Name Representing Role Since Contact
Info
Abraham Van Wyk GRI Bio Board Member 000 0000
Albert Agro Ph.D Self Senior Vice President of Clinical Development, Board Member and Co-Founder 000 0000
Marc Hertz Ph.D GRI Bio Co-Founder, Chairman & Chief Executive Officer 000 0000
Vipin Chaturvedi Ph.D GRI Bio Chief Scientific Officer, Board Member and Co-Founder 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »